U
39.30
0.33 (0.85%)
前收盘价格 | 38.97 |
收盘价格 | 39.20 |
成交量 | 1,044,500 |
平均成交量 (3个月) | 822,321 |
市值 | 3,566,310,400 |
价格/销量 (P/S) | 4.94 |
股市价格/股市净资产 (P/B) | 19.89 |
52周波幅 | |
利润日期 | 30 Apr 2025 - 5 May 2025 |
营业毛利率 | -93.04% |
营业利益率 (TTM) | -102.62% |
稀释每股收益 (EPS TTM) | -5.83 |
季度收入增长率 (YOY) | 28.00% |
总债务/股东权益 (D/E MRQ) | 588.24% |
流动比率 (MRQ) | 2.40 |
营业现金流 (OCF TTM) | -389.94 M |
杠杆自由现金流 (LFCF TTM) | -172.94 M |
资产报酬率 (ROA TTM) | -24.51% |
股东权益报酬率 (ROE TTM) | -377.06% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 混合的 | |
股票 | Ultragenyx Pharmaceutical Inc. | 看涨 | 看跌 |
AIStockmoo 评分
1.5
分析师共识 | 3.5 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 2.0 |
平均 | 1.50 |
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Core |
内部持股比例 | 3.20% |
机构持股比例 | 99.43% |
52周波幅 | ||
目标价格波幅 | ||
高 | 128.00 (Canaccord Genuity, 225.70%) | 购买 |
中 | 65.00 (65.39%) | |
低 | 34.00 (Wedbush, -13.49%) | 保留 |
平均值 | 75.86 (93.03%) | |
总计 | 6 购买, 1 保留 | |
平均价格@调整类型 | 31.07 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
HC Wainwright & Co. | 09 Sep 2025 | 80.00 (103.56%) | 购买 | 31.50 |
28 Jul 2025 | 80.00 (103.56%) | 购买 | 27.61 | |
Cantor Fitzgerald | 05 Sep 2025 | 105.00 (167.18%) | 购买 | 31.82 |
06 Aug 2025 | 105.00 (167.18%) | 购买 | 28.05 | |
Canaccord Genuity | 08 Aug 2025 | 128.00 (225.70%) | 购买 | 27.54 |
Morgan Stanley | 14 Jul 2025 | 55.00 (39.95%) | 购买 | 29.23 |
Wedbush | 14 Jul 2025 | 34.00 (-13.49%) | 保留 | 29.23 |
Wells Fargo | 10 Jul 2025 | 65.00 (65.39%) | 购买 | 31.04 |
Guggenheim | 20 Jun 2025 | 64.00 (62.85%) | 购买 | 37.14 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合